Search PubMed⌕ Search

Biomedical subjects

A Lindner

Publications and source records attributed to A Lindner.

At least 181 records · Page 10Linked to original sources
PubMed1987

Effects of a circulating factor in patients with essential hypertension on intracellular free calcium in normal platelets.

Intracellular free (cytosolic) calcium has been reported to be increased in the platelets of patients with essential hypertension. We investigated the possibility that the high cytosolic calcium concentration may be caused by a circulating plasma factor, by incubating platelets from normotensive subjects with plasma ultrafiltrates from patients with essential hypertension. The cytosolic calcium concentration in normal platelets increased after incubation with plasma from patients with untreated hypertension (80 +/- 15 percent [+/- SEM]) or from patients in whom hypertension was well controlled by calcium-influx blockers (129 +/- 33 percent). In contrast, the cytosolic calcium concentration was unchanged after incubation with plasma from normotensive subjects. When platelets from the patients were incubated with plasma from the controls, cytosolic calcium in platelets decreased by more than 30 percent, into the normal range (P less than 0.01). These data demonstrate that plasma from patients with essential hypertension contains a substance that increases the cytosolic calcium concentration in platelets. Cytosolic calcium is a trigger for vascular smooth-muscle-cell contraction, and if the plasma factor acts on these cells as it acts on platelets, it may be responsible for the increased peripheral vascular resistance associated with hypertension.

Adult↗
PubMed1987

Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension.

A double-blind controlled, randomized, parallel, multicenter 12-week study was conducted to compare the antihypertensive efficacy of lisinopril with that of metoprolol in treatment of moderate to severe hypertension. Initially, 118 patients were recruited on lisinopril and 61 on metoprolol; and for the purpose of efficacy analysis at week 8, 115 patients on lisinopril and 60 on metoprolol were included. The doses of lisinopril or metoprolol were 40-80 mg/day and 100-200 mg/day, respectively. At week 4, the pretreatment diastolic blood pressure of 111 mm Hg was decreased to 97 mm Hg (p less than 0.01) with lisinopril: metoprolol decreased the diastolic blood pressure from 110 to 99 mm Hg (p less than 0.01). Similar decreases were noted at week 8; however, the drop in blood pressure with lisinopril was not significantly different from that with metoprolol. Systolic blood pressure also demonstrated a decrease of about 18 mm Hg with lisinopril and 12 mm Hg with metoprolol (p less than 0.01). This larger decrease in systolic blood pressure with lisinopril was statistically significant at week 4 (p less than 0.05). These decreases in systolic blood pressures were maintained at week 8, again with statistical significance (p less than 0.01). Of the 118 lisinopril-treated patients, four were discontinued from lisinopril therapy because of headache, dizziness, rash, flushing, or lymphadenopathy. Four patients out of 61 (9.8%) were discontinued from metoprolol therapy because of fatigue, somnolence, asthenia, weight gain, flatulence, tremor, or bronchospasm. In conclusion, lisinopril 40-80 mg once daily is as effective as metoprolol 100-200 mg once daily in reducing diastolic blood pressure in patients with moderate to severe hypertension.(ABSTRACT TRUNCATED AT 250 WORDS)

Age Factors↗
PubMed1987

Local hyperthermia of the prostate gland for the treatment of benign prostatic hypertrophy and urinary retention. A preliminary report.

The Prostathermer (TM), a system designed to deliver hyperthermic treatment to the prostate gland, was used to treat six patients with benign prostatic hypertrophy and urinary retention. The 99-D model consists of a microwave generator operating at 915 MHz, an applicator with a built-in water cooling system, temperature probes and an IBM PC-XT type computer. The treatment regimen differed from patient to patient in the number of treatments (range 5-10), frequency per week (range 1-2), and average radiofrequency (RF) transmission. Sustained controlled heating of the prostatic tissue up to 39.4 to 45.2 degrees C was carried out for 60 min in each session. Five patients were relieved of their indwelling catheters and at follow-up 6 months after termination of therapy they were well by objective and subjective criteria. No complications were encountered. This is preliminary report of our results of treatment with 47 hyperthermic sessions in six patients.

Aged↗
PubMed1986

Maxillary expansion of unilateral cross-bite in preschool children.

The influence of a low force appliance on the maxilla in correction of unilateral cross-bite was studied clinically and radiographically in 29 preschool children following a standardized treatment schedule. Four weeks' expansion was followed by a 4-wk retention and a 12-wk postretention period. Inter- and intraobserver evaluations of the reliability of the measurements on radiographs were performed. In all children but one the cross-bites were corrected after 4 wk of expansion. The mean maxillary expansion was 3.3 mm in the second molar and 1.3 mm in the canine region, but decreased to 1.5 mm and 1.0 mm, respectively, at the end of the postretention period without relapse of the corrected malocclusion. No significant remaining orthopedic effects could be registered on radiographs by this low force appliance used. The modified quad helix appliance was found to be suitable for correction of unilateral cross-bite in the primary dentition and was well tolerated by the children.

Child, Preschool↗
PubMed1985

Urinary bladder tumors following cyclophosphamide therapy: a report of two cases with a review of the literature.

Sterile hemorrhagic cystitis following cyclophosphamide (Cph) therapy is a relatively frequent and well-documented phenomenon. On the other hand, cancer of the urinary bladder associated with Cph therapy is rarely observed. We present two cases and summarize 32 patients reported in the literature. Thirty patients had malignant disease elsewhere, 27 of them nonsolid tumors. The other four patients received treatment with Cph for nonmalignant disease (systemic lupus erythematosus--3; rheumatoid arthritis--1). The bladder tumor developed several months to years after treatment. In 20 patients hemorrhagic cystitis antedated the tumors. We conclude that hemorrhagic cystitis in patients on Cph therapy should indicate at least temporary withdrawal of the drug. The decision to resume treatment should be taken with extreme caution considering the risk of the development of bladder cancer.

Adolescent↗
PubMed1985

Treatment of patients with transitional cell carcinoma of the urinary bladder with intravesical poly I: poly C effects on natural killer function.

Considerable interest has been focused on the use of interferon (IFN) and IFN-inducers as antineoplastic agents in humans. The current report will focus on the effect of intravesical administration of Poly I: Poly C on NK activity in patients with TCC of the urinary bladder. NK cytotoxicity was measured in 14 patients with primary TCC, 8 patients received Poly I: Poly C and 5 other patients received intravesical thiotepa. Blood samples were obtained prior to and 48 h following each drug treatment. A variation in the initial NK level determined prior to treatment was observed in the different TCC patients: 5 patients treated with Poly I: Poly C and 5 patients treated with thiotepa exhibited low NK activity prior to treatment, whereas the other 3 patients who were treated with Poly I: Poly C had high initial NK levels. Following drug treatment it was shown that a significant elevation in the NK cytotoxicity was only observed in patients treated by intravesical Poly I: Poly C who had low NK activity prior to treatment. No such effect was observed in patients treated with thiotepa or in patients treated with Poly I: Poly C who exhibited a high NK activity prior to treatment.

Adult↗
PubMed1985

Primary chondrosarcoma of the kidney.

Primary chondrosarcoma of the extraskeletal soft tissue is rare, usually occurring in the upper and lower extremities. We report the first case of this neoplasm arising in the kidney.

Chondrosarcoma↗
PubMed1985

The use of collagenase in the treatment of Peyronie's disease.

Purified clostridial collagenase was administered intralesionally in 31 men with Peyronie's disease. Within 4 weeks of treatment 20 patients showed an objective improvement. Pain was eliminated in 13 of 14 patients with this complaint at presentation within the same 4-week period. The ability to have intercourse was restored in 3 of 4 patients with this problem. Except for a small corporeal rupture at the site of injection in 1 patient, no significant untoward effects were noted. During the mean 9.8-month followup 1 recurrence of bending was noted.

Adult↗
PubMed1985

The management of superficial bladder tumors and carcinoma in situ with intravesical bacillus Calmette-Guerin.

A phase II study was performed to assess the role of bacillus Calmette-Guerin as a prophylaxis against recurrent stages O and A bladder tumors, and in the treatment of existing superficial bladder tumors and carcinoma in situ. Tice strain bacillus Calmette-Guerin (1 vial, 2 to 8 times 10(8) organisms in 60 cc saline) was instilled intravesically without cutaneous inoculation. Instillations were given weekly for 6 weeks and then monthly or until recurrence in 22 patients with a history of recurrent tumors, while 22 with existing stages O and A transitional cell carcinoma, and 19 with carcinoma in situ were treated weekly for 8 weeks and then monthly for 12 months or until failure. Complications included cystitis in 88 per cent of the patients (severe in 20 per cent), fever in 15 per cent, a flu-like syndrome in 13 per cent, edema and pruritus in 1.5 per cent, and ureteral stenosis in 1.5 per cent. Twelve patients (19 per cent) did not complete the study owing to toxicity. Of the patients in the prophylaxis group 67 per cent have had no tumor recurrence 10 to 26 months (mean 15 months) after therapy. Of the patients with existing tumors 36 per cent had complete regression following bacillus Calmette-Guerin therapy and 23 per cent had a partial response. Among the patients with carcinoma in situ 13 (68 per cent) had reversal to normal urothelium and 3 (16 per cent) had marked improvement. None of the patients had recurrence at 11 to 20 months. Intravesical Tice strain bacillus Calmette-Guerin is effective as a prophylaxis against recurrent superficial bladder tumors and in the treatment of carcinoma in situ.

BCG Vaccine↗
PubMed1984

Ileourethral fistula following cystectomy: a rare complication.

Fistulae between the urinary and intestinal tracts of adult male patients usually result from trauma, inflammatory diseases, necrosis and infiltration of a neoplasm of either the bladder, prostate or colon, or radiation therapy. We report 2 patients who developed an ileourethral fistula following cystectomy which had been performed for carcinoma of the bladder in 1 patient and leukoplakia of the bladder in the other. The diagnosis of an ileourethral fistula was established by retrograde urethrography and a barium follow-through study. Computed tomography performed in 1 patient showed a tumor mass in the pelvis.

Aged↗
PubMed1984

Squamous cell carcinoma presenting 10 years after cystectomy for leukoplakia.

Leukoplakia of the bladder is widely accepted as a precancerous lesion. We describe a patient in whom squamous cell carcinoma presented as an enterourethral fistula 10 years after cystectomy for leukoplakia of the bladder. During cystectomy we left most of the prostate and posterior urethra intact to preserve potency. In view of this case we recommend that in patients with bladder leukoplakia in whom ablative surgery is being contemplated a complete cystoprostatectomy be performed and a urethrectomy be considered seriously.

Adult↗
PubMed1984

Effects of verapamil and nifedipine on renal function and hemodynamics in the dog.

This study evaluates the direct effects of verapamil (5 micrograms/kg/min) or nifedipine (0.32 micrograms/kg/min) when infused into one renal artery for 2 h. The role of calcium in the systemic and renal vascular effects of angiotensin II (1 microgram/i.v. bolus) was examined in each period. Renal blood flow was increased 11% by verapamil and 29% by nifedipine. Unlike other vasodilators, these drugs markedly increased GFR (by 75% with verapamil and 50% with nifedipine), and both caused a profound natriuresis, which outlasted the renal hemodynamic changes. Further, they abolished the renal vascular responses to angiotensin II. These major direct effects on renal function and hemodynamics suggest that: (a) calcium blockers may affect the determinants of GFR differently from other vasodilators, and (b) they may interfere with proximal tubular Na+ transport.

Angiotensin II↗